logo

MediciNova Announces Acceptance of Abstract Regarding MN-166 ( ibudilast ) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS ( Northeast Amyotrophic Lateral Sclerosis Consortium ) Meeting

  2 weeks ago   
post image
LA JOLLA, Calif., Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market ( NASDAQ:MNOV ) and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , today announced that an abstract was accepted for presentation ...
Ticker Sentiment Impact
MNOV
Neutral
27 %